MAZE PE Ratio & Valuation,Is MAZE Overvalued

MAZE Relative Valuation

MAZE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MAZE is overvalued; if below, it's undervalued.

Historical Valuation

Maze Therapeutics Inc (MAZE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.46. The fair price of Maze Therapeutics Inc (MAZE) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：39.82

Fair

-12.78

-9.52

EV/EBITDA

Maze Therapeutics Inc. (MAZE) has a current EV/EBITDA of -9.52. The 5-year average EV/EBITDA is -5.15. The thresholds are as follows: Strongly Undervalued below -11.74, Undervalued between -11.74 and -8.45, Fairly Valued between -1.86 and -8.45, Overvalued between -1.86 and 1.43, and Strongly Overvalued above 1.43. The current Forward EV/EBITDA of -9.52 falls within the Undervalued range.

-9.65

EV/EBIT

Maze Therapeutics Inc. (MAZE) has a current EV/EBIT of -9.65. The 5-year average EV/EBIT is -4.73. The thresholds are as follows: Strongly Undervalued below -10.10, Undervalued between -10.10 and -7.42, Fairly Valued between -2.05 and -7.42, Overvalued between -2.05 and 0.63, and Strongly Overvalued above 0.63. The current Forward EV/EBIT of -9.65 falls within the Undervalued range.

1454.40

Maze Therapeutics Inc. (MAZE) has a current PS of 1454.40. The 5-year average PS is 320.22. The thresholds are as follows: Strongly Undervalued below -602.79, Undervalued between -602.79 and -141.29, Fairly Valued between 781.73 and -141.29, Overvalued between 781.73 and 1243.24, and Strongly Overvalued above 1243.24. The current Forward PS of 1454.40 falls within the Strongly Overvalued range.

-14.25

P/OCF

Maze Therapeutics Inc. (MAZE) has a current P/OCF of -14.25. The 5-year average P/OCF is -7.78. The thresholds are as follows: Strongly Undervalued below -14.60, Undervalued between -14.60 and -11.19, Fairly Valued between -4.37 and -11.19, Overvalued between -4.37 and -0.96, and Strongly Overvalued above -0.96. The current Forward P/OCF of -14.25 falls within the Undervalued range.

-12.64

P/FCF

Maze Therapeutics Inc. (MAZE) has a current P/FCF of -12.64. The 5-year average P/FCF is -6.20. The thresholds are as follows: Strongly Undervalued below -12.30, Undervalued between -12.30 and -9.25, Fairly Valued between -3.15 and -9.25, Overvalued between -3.15 and -0.10, and Strongly Overvalued above -0.10. The current Forward P/FCF of -12.64 falls within the Strongly Undervalued range.

Maze Therapeutics Inc (MAZE) has a current Price-to-Book (P/B) ratio of 5.04. Compared to its 3-year average P/B ratio of 1.99 , the current P/B ratio is approximately 152.96% higher. Relative to its 5-year average P/B ratio of 1.99, the current P/B ratio is about 152.96% higher. Maze Therapeutics Inc (MAZE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.90%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 1.90% , the current FCF yield is about -100.00% lower.

5.04

P/B

Median3y

1.99

Median5y

1.99

-5.78

FCF Yield

Median3y

1.90

Median5y

1.90

Competitors Valuation Multiple

The average P/S ratio for MAZE's competitors is 3.01, providing a benchmark for relative valuation. Maze Therapeutics Inc Corp (MAZE) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MAZE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MAZE in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Maze Therapeutics Inc (MAZE) currently overvalued or undervalued?

What is Maze Therapeutics Inc (MAZE) fair value?

MAZE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Maze Therapeutics Inc (MAZE) is between to according to relative valuation methord.

How does MAZE's valuation metrics compare to the industry average?

The average P/S ratio for MAZE's competitors is 3.01, providing a benchmark for relative valuation. Maze Therapeutics Inc Corp (MAZE) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for Maze Therapeutics Inc (MAZE) as of Dec 16 2025?

As of Dec 16 2025, Maze Therapeutics Inc (MAZE) has a P/B ratio of 5.04. This indicates that the market values MAZE at 5.04 times its book value.

What is the current FCF Yield for Maze Therapeutics Inc (MAZE) as of Dec 16 2025?

As of Dec 16 2025, Maze Therapeutics Inc (MAZE) has a FCF Yield of 0.00%. This means that for every dollar of Maze Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Maze Therapeutics Inc (MAZE) as of Dec 16 2025?

As of Dec 16 2025, Maze Therapeutics Inc (MAZE) has a Forward P/E ratio of -12.78. This means the market is willing to pay $-12.78 for every dollar of Maze Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Maze Therapeutics Inc (MAZE) as of Dec 16 2025?

As of Dec 16 2025, Maze Therapeutics Inc (MAZE) has a Forward P/S ratio of 0.00. This means the market is valuing MAZE at $0.00 for every dollar of expected revenue over the next 12 months.

MAZE Valuation